Drug Profile
Research programme: cancer therapeutics - Novartis/Servier/Vernalis
Alternative Names: Bcl-2 inhibitors; Mcl-1 inhibitors; S63845Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Servier; Vernalis
- Developer Emory University; Servier; University of California at Irvine; Vernalis
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis regulatory protein inhibitors; MCL1 protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cancer; Multiple myeloma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (Parenteral)
- 04 Feb 2022 Pharmacodynamics data from preclinical studies in Multiple myeloma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)